DEVELOPMENT AND VALIDATION OF DEFERASIROX-RELATED SUBSTANCE METHOD IN SOLID DOSAGE FORMS USING HPLC
DOI:
https://doi.org/10.22159/ijap.2025v17i2.53465Keywords:
Deferasirox, Related Substances, Impurity, Validation, Forced Degradation, High-performance liquid chromatographyAbstract
Objective: A simple, sensitive, and reproducible Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) method was developed to quantitatively determine related substances in bulk and pharmaceutical dosage forms of Deferasirox (DFS). The method's performance was validated according to the present International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guidelines for specificity, limit of detection (LOD), limit of quantification (LOQ), linearity, accuracy, precision, and Robustness. The developed method can be used for routine analysis of the determination of DFS in the presence of degradation products and impurities.
Methods: Chromatographic separation was achieved on Shimadzu shim pack GIS (150*4.6) mm5µm using isocratic elution mode, which included 0.1 % Formic acid in Water: Acetonitrile in gradient mode as mobile phase at a flow rate of 1.0 ml/min. And column temperature of 40 °C. Detection was performed at a wavelength of 254 nm coupled with an Ultra Violet (UV) detector. The Injection volume was 10 µl. The drug was exposed to various stress conditions in degradation studies, such as acidic, basic, oxidative, hydrolytic, photolytic, and thermal degradation.
Results: The retention time of DFS was 8.1 min. The resolution of DFS and four impurities was greater than 2.0 for all pairs of components. The high correlation coefficient (r2>0.9990) values indicated clear correlations between the investigated compound concentrations and their peak areas within the test ranges. The Repeatability and intermediate precision expressed by the Relative Standard Deviation (RSD) were less than 10%. The accuracy evaluated by performing recovery studies via a spike method was 50-150%. Stress Degradation studies were carried out; however, no significant degradation was observed in any of the stress degradation conditions, implying a chemically stable drug formulation and the method used to measure stability is robust to minor variations; hence, the product is likely to maintain its quality and efficacy throughout its shelf life.
Conclusion: Hence, a suitable, reliable, accurate, precise, and economical HPLC method was developed, which is ideal for analyzing DFS in both bulk and commercial formulations.
References
Pantopoulos K, Porwal SK, Tartakoff A, Devireddy L. Mechanisms of mammalian iron homeostasis. Biochemistry. 2012;51(29):5705-24. doi: 10.1021/bi300752r, PMID 22703180.
Halliwell B, Gutteridge JM. Free radicals and antioxidant protection: mechanisms and significance in toxicology and disease. Hum Toxicol. 1988;7(1):7-13. doi: 10.1177/096032718800700102, PMID 3278973.
Singer ST. Variable clinical phenotypes of α-thalassemia syndromes. Scientific World Journal. 2009;9:615-25. doi: 10.1100/tsw.2009.69, PMID 19618088.
Galanello R, Cao A. Relationship between genotype and phenotype. Thalassemia intermedia. Ann N Y Acad Sci. 1998;850:325-33. doi: 10.1111/j.1749-6632.1998.tb10489.x, PMID 9668554.
Borgna Pignatti C. Modern treatment of thalassaemia intermedia. Br J Haematol. 2007;138(3):291-304. doi: 10.1111/j.1365-2141.2007.06654.x, PMID 17565568.
Pippard MJ, Callender ST, Warner GT, Weatherall DJ. Iron absorption and loading in β-thalassemia intermedia. Lancet. 1979;2(8147):819-21. doi: 10.1016/s0140-6736(79)92175-5, PMID 90918.
FDA approves first oral drug for chronic iron overload. US Food and Drug Administration; 2015.
Deferasirox. PubChem compound summary; 2023. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/deferasirox. [Last accessed on 25 Feb 2025]
Olsen BA, Sreedhara A, Baertschi SW. Impurity investigations by phases of drug and product development. Trac Trends Anal Chem. 2018;101:17-23. doi: 10.1016/j.trac.2017.10.025.
Singh D, Isharani R. A detailed review on analytical methods to manage the impurities in drug substances. OALIB. 2023;10(8):1-18. doi: 10.4236/oalib.1110223.
Jahani M, Fazly Bazzaz BS, Akaberi M, Rajabi O, Hadizadeh F. Recent progresses in analytical perspectives of degradation studies and impurity profiling in pharmaceutical developments: an updated review. Crit Rev Anal Chem. 2023;53(5):1094-115. doi: 10.1080/10408347.2021.2008226, PMID 35108132.
Vekariya N, Gupta P, Islam A. Synthesis and characterization of related substances of deferasirox, an iron (Fe3+) chelating agent. Int J Rapid Commun Synth Org Chem. 2012;42(21):3200-10.
ICH. Q2A validation of analytical procedures: consensus guidelines. ICH harmonized tripartite guidelines; 1994.
Conference for harmonization, Impurities in New Drug products Q3B. ICH harmonized tripartite guidelines. Vol. R2; 2006.
International Conference for Harmonization. Validation of Analytical Procedures: text and methodology. Vol. Q2. Geneva; 2005. p. R1.
Somisetty V, Dhachinamoorthi D, Rahaman S. Development and validation of newer analytical methods for the estimation of deferasirox in bulk and in tablet dosage form by UV spectroscopy and RP–HPLC. Int J Chem Tech Res. 2013;5:1861-8.
Tiwari PK, Sathe P, Devadiga N. Low level determination of genotoxic impurity in deferasirox formulation. J Anal Sci Methods Instrum. 2013;3(4):179-83. doi: 10.4236/jasmi.2013.34023.
Vattikuti R, Phani R, Seetharaman R. RP-HPLC method development for analysis of deferasirox in the formulation. IJPI’s J Anal Chem. 2011;4:30-5.
Khan M, Sinha S, Todkar M, Parashar V, Reddy K, Kulkarni U. Validated HPLC-UV method for simultaneous estimation of deferasirox and its impurities. Int J Pharm Biomed Res. 2011;2:128-34.
Chakravarthy V, Sankar D. LC determination of deferasirox in pharmaceutical formulation. J Glob Trends Pharm Sci. 2010;1:42-52.
Padmaja N, Ramathilagam N. Method development and validation of RP-HPLC method for the determination of deferasirox in tablets. Int J Pharm Bio Sci. 2012;2:338–3439.
Ettaboina SK, Nakkala K, Chathalingath N. Development and validation of rapid RP-HPLC method for determination of deferasirox in bulk and tablet dosage forms. Asian J Pharm Anal. 2022 May;12(02).
Kothawade J, Agrawal K, Lad V. Stability indicating RP-HPLC assay method development and validation for determination of deferasirox in tablet dosage form. Int J Pharm Res Allied Sci. 2012;1:40-5.
Prakash S, Chaitanya S, Neetha K. Stability indicating RP-HPLC method for the determination of deferasirox in bulk drug and pharmaceutical dosage forms. Unique Res J Chem. 2013;1(1):35-40.
Bhatt N, Dhrubjyoti S. Comparative stability-indicating assay method of deferasirox by RP-HPLC and HPTLC. World J Pharm Res. 2016;5(9):1252-79.
Anandakumar K, Chinthala R, Subhash V, Jayamariappan M. Development and validation of newer analytical methods for the estimation of deferasirox in bulk and tablet dosage form by UV spectroscopy and RP-HPLC. J Pharm Res. 2011;4(9):2998-3000.
Shishodia T, Grover P, Nagarajan K, Bhardwaj M, Chopra B. Development and validation of robust, highly sensitive and stability-indicating RP-HPLC method for estimation of deferasirox and its degradation products. J Chromatogr Sci. 2024;62(8):709-18. doi: 10.1093/chromsci/bmad032, PMID 37070383.
Saravanan S, Swetha R. Method development and validation for determination of impurities in deferasirox by RP-HPLC technique. J Drug Deliv Ther. 2012;2(3):148-52. doi: 10.22270/jddt.v2i3.128.
Published
How to Cite
Issue
Section
Copyright (c) 2025 RUJUTA TRIVEDI, BHANUBHAI SUHAGIA
This work is licensed under a Creative Commons Attribution 4.0 International License.
